Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

被引：0
作者：
A Tchirkov
J-L Couderc
B Périssel
C Goumy
A Regnier
N Uhrhammer
P Verrelle
M Berger
机构：
[1] Centre Jean Perrin,
[2] Service de Cytogénétique Médicale,undefined
[3] CHU – Faculté de Médecine,undefined
[4] UMR 384 INSERM,undefined
[5] Service de Médecine Interne,undefined
[6] CH,undefined
[7] Hématologie,undefined
[8] Faculté de Médecine,undefined
来源：
Leukemia | 2006年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：167 / 168
页数：1
相关论文
共 50 条
[31]   Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib [J].
Barbosa Pagnano, Katia Borgia ;
Miranda, Eliana Cristina ;
Delamain, Marcia Torresan ;
Duarte, Gislaine Oliveira ;
de Paula, Erich Vinicius ;
Lorand-Metze, Irene ;
de Souza, Carmino Antonio .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11) :728-733
[32]   Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts [J].
Sharma, Pratibha ;
Kumar, Lalit ;
Mohanty, Sujata ;
Kochupillai, Vinod .
ANNALS OF HEMATOLOGY, 2010, 89 (03) :241-247
[33]   BCR-ABL fusion gene and BCR-ABL transcript -: Correlation with response to therapy in Chronic Myeloid Leukaemia. [J].
Geraldes, C ;
Gonçalves, AC ;
Santos, P ;
Tavares, P ;
Teixeira, A .
BLOOD, 2005, 106 (11) :297B-297B
[34]   Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts [J].
Pratibha Sharma ;
Lalit Kumar ;
Sujata Mohanty ;
Vinod Kochupillai .
Annals of Hematology, 2010, 89 :241-247
[35]   Molecular deregulations mediated by Bcr-Abl in chronic myeloid leukemia [J].
Chomel, JC ;
Guilhot, F ;
Tanzer, J ;
Kitzis, A .
M S-MEDECINE SCIENCES, 1995, 11 (12) :1669-1678
[36]   BCR-ABL: The molecular mastermind behind chronic myeloid leukemia [J].
Shammas, Tara ;
Peiris, Malalage N. ;
Meyer, April N. ;
Donoghue, Daniel J. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2025, 83 :45-58
[37]   Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia [J].
Radich, Jerald P. .
CANCER, 2012, 118 (02) :300-311
[38]   Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript [J].
Lucas, Claire M. ;
Harris, Robert J. ;
Giannoudis, Athina ;
Davies, Andrea ;
Knight, Katy ;
Watmough, Sarah J. ;
Wang, Lihui ;
Clark, Richard E. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10) :1362-1367
[39]   Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia [J].
Sun, Xiaoyan ;
Cai, Xueting ;
Yang, Jie ;
Chen, Jiao ;
Guo, Caixia ;
Cao, Peng .
MOLECULES AND CELLS, 2016, 39 (12) :869-876
[40]   Chronic Myeloid Leukemia: Clinical Prestantation According to Bcr-Abl Transcript Variants [J].
Acosta Hernandez, Titania del Carmen ;
Best Aguilera, Carlos Roberto ;
Villela Martinez, Luis Mario ;
Guzman Hernandez, Alicia Elizabeth ;
Robles Rodriguez, Arianna ;
Lopez Hernandez, Juan Carlos ;
Gomez Vazquez, Oscar Rodrigo ;
Rivera Mendoza, Laura Adriana ;
Garcia Reyes, Barbara ;
Gutierrez Alatorre, Aldo Fernando Adrian ;
Calderon Valdez, Areli Sarai ;
Visuetti Pimentel, Saribethe Mahely .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 :S243-S243
12345